Niaprazine
| |
| Niaprazine
| |
| Systematic (IUPAC) name | |
| N-[4-[4-(4-fluorophenyl)piperazin-1-yl]butan-2-yl]pyridine-3-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| Chemical data | |
| Formula | C20H25FN4O |
| Mol. mass | 356.437 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 4.53 +- 0.86 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Niaprazine | |
|
Articles | |
|---|---|
|
Most recent articles on Niaprazine | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Niaprazine at Clinical Trials.gov Clinical Trials on Niaprazine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Niaprazine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Niaprazine Discussion groups on Niaprazine Patient Handouts on Niaprazine Directions to Hospitals Treating Niaprazine Risk calculators and risk factors for Niaprazine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Niaprazine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Overview
Niaprazine (Nopron) is a piperazine derivative drug which acts as a sedating antihistamine. It was invented in the 1970s [1], and is used in France, Italy and other european countries. It is mainly prescribed for its relatively strong sedative effects rather than as an antihistamine, and is used mainly for treating autism [2] and insomnia [3] in children and adolescents. Common side effects are: sedation during the day (especially during the first few days of treatment) and dizziness.
References
- ↑ Duchene-Marullaz P, Rispat G, Perriere JP, Hache J, Labrid C. Some pharmacodynamical properties of niaprazine, a new antihistaminic agent. (French) Therapie. 1971 Nov-Dec;26(6):1203-9.
- ↑ Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M. Niaprazine in the treatment of autistic disorder. Journal of Child Neurology. 1999 Aug;14(8):547-50.
- ↑ Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatric Drugs. 2002;4(6):391-403.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
